Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06142396 · ClinicalTrials.gov registry record · Early Phase 1
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
A Early Phase 1 study of Multiple Myeloma and Renal Failure, sponsored by Augusta University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06142396 is a Early Phase 1 study of Multiple Myeloma and Renal Failure that is actively recruiting participants, run by Augusta University. The registered enrollment target is 30 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06142396, a Early Phase 1 study of Multiple Myeloma and Renal Failure, is actively recruiting participants, sponsored by Augusta University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to assess the efficacy of induction treatment with daratumumab-hyaluronidase (dara SC) with cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) for four cycles in patients with newly diagnosed multiple myeloma who have new onset renal failure. This study will also investigate the difference responses in African American (AA) patients versus non-African American patients. The primary questions this study aims to answer are: 1. To evaluate the very good partial response rate (VGPR) after 4 cycles of Dara-CyBord. 2. To evaluate the renal response rate (RRR) after 4 cycles of Dara-CyBord.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone
Study Locations (1)
Georgia
- Georgia Cancer Center-Augusta University - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-11-01 |
| Est. Completion | 2027-11-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06142396
The ClinicalTrials.gov registry entry for NCT06142396 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (95% lower). The listed sponsor is Augusta University, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone is the first listed.
NCT06142396 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT06142396 about?
NCT06142396 is a clinical study titled "Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure". The goal of this study is to assess the efficacy of induction treatment with daratumumab-hyaluronidase (dara SC) with cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) for four cycles in patients with newly diagnosed multiple myeloma who have new onset renal failure. This study will also...
What is the current status of trial NCT06142396?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2024-11-01. Estimated completion is 2027-11-01.
What conditions does trial NCT06142396 study?
This clinical trial studies the following conditions: Multiple Myeloma, Renal Failure.
What interventions are being tested in trial NCT06142396?
The interventions under investigation include: Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06142396?
This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06142396 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
RECRUITING · Early Phase 1
-
VitD3 Supplementation in Patients With Multiple Myeloma
RECRUITING · Early Phase 1
-
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
RECRUITING · Early Phase 1
-
Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma
RECRUITING · Early Phase 1
-
64Cu-LLP2A for Imaging Hematologic Malignancies
RECRUITING · Early Phase 1
-
A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.